Thorium-227 labeled antibody-chelator conjugate
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Thorium-227 labeled antibody-chelator conjugate, covering 2024-11-08 to 2024-11-08. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]